Microbot Medical Inc. · NASDAQ:MBOT
Microbot Medical — Investor Presentation (March 2021)
26 slides from Microbot Medical's investor presentation, March 2021
Slide 1: Robotizing Endoluminal Surgery
ROBOTIZING ENDOLUMINAL SURGERY NASDAQ:MBOT
Slide 2: Safe Harbor Statement
SAFE HARBOR STATEMENT This document contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, relating to future events or the future financial performance and operations of Micr
Slide 3: Medical Robotics Market Is Rapidly Growing
MEDICAL ROBOTICS MARKET IS RAPIDLY GROWING Minimally Invasive Surgery Expected (MIS) is the fastest growing healthcare segment >20% CAGR >$50B through 2025 Applies to Becoming Most Surgical Smaller, Automated, Specialties and More Precise 3
Slide 4: Surgical Robotics Growth Opportunity
SURGICAL ROBOTICS GROWTH OPPORTUNITY U.S. Market for Surgical Robotics 19 Million ~95% +15-20% Procedures in 2019 of Addressable Market Market Growth >5% used a Robotic Remains Available in Endoluminal Robotic Device Surgery by 2025 (est.) Microbot Medical is in the Right Market, at the Right Time w
Slide 5: Healthcare Landscape: Positioned for Post COVID-19
HEALTHCARE LANDSCAPE POSITIONED FOR POST COVID-19 Telehealth has been a core Cardiovascular Today, April 2020 focus of Microbot’s product COVID-19: Robotics may help to reduce exposure development roadmap to virus patients during interventional procedures LIBERTY and SCS are ResearchGate, March 2020
Slide 6: Medical Robotics Remains in the Spotlight
MEDICAL ROBOTICS REMAINS IN THE SPOTLIGHT Medtronic Announces Acquisition of Digital Surgery to Accelerate Robot Assisted Surgery Strategy. Globe Newswire, February 2020 Intuitive Surgical Acquires Orpheus Medical for Undisclosed Amount. Globe Newswire, February 2020 Stryker Acquires Mobius Imaging
Slide 7: Evolution of Surgery
EVOLUTION OF SURGERY Tomorrow Micro-robotics Today Robot Assisted Surgery 1990-2000 Minimally Invasive Surgery 1980-1990 Freehand Surgery 7
Slide 8: Multiple Opportunities – Endoluminal Surgery
MULTIPLE OPPORTUNITIES – ENDOLUMINAL SURGERY 8
Slide 9: Building on a Successful Track Record…
BUILDING ON A SUCCESSFUL TRACK RECORD… Strong LIBERTY Robotic System Successful Pre-submission Balance Sheet Validated Through Multiple Meeting with the FDA Feasibility Studies Regarding the SCS Robust IP Portfolio: Thought Leaders to Enhance Core Capabilities 41 Global Patents • Expanded Management
Slide 10: …Continued Momentum in 2021
…CONTINUED MOMENTUM IN 2021 Conclude animal feasibility studies on LIBERTY Robotic System LIBERTY Robotic System design freeze Initiate Animal Study in LIBERTY Robotics System Concluded SCS Pre-Submission meeting with the FDA FDA pre-submission request for LIBERTY Robotic System Explore M&A opportun
Slide 11: ibe
ibe microbot medicol
Slide 12: Fully Disposable Robotic System
FULLY DISPOSABLE ROBOTIC SYSTEM Eliminate Need for Capital Equipment Operated Remotely “One & Done” Capabilities 13
Slide 13: Total Addressable Market - Vascular
TOTAL ADDRESSABLE MARKET - VASCULAR ~800K Stroke Incidences, US Neuro Only ~4% Treated 3+ M procedures WW Coronary 2+ M procedures WW Peripheral 14 *** Microbot Confidential ***
Slide 14: Animal Feasibility Studies
ANIMAL FEASIBILITY STUDIES First Study End Points Met Peripheral and Neuro Procedures Successfully Achieved No Intraoperative Adverse Effects Exceed internal expectations Confirmed Usability of the System with Leading KOL’s *The LIBERTY Robotic System is under its R&D phase, was not tested clinicall
Slide 15: 16
16
Slide 16: Animal Feasibility Studies: Second Study End Point Met
ANIMAL FEASIBILITY STUDIES Second Study End Point Met Navigated to a clot Crossed the clot Deployed a stent retriever Retrieved an arterial clot in a live pig (manually) CROSSING THE CLOT INSERTION OF STENT RETRIEVER *All of the end points were met with no intraoperative adverse events. 17
Slide 17: MAKI - 10513. MRT - 10513
MAKI - 10513. MRT - 10513 10513 Standard 190.3 mGy 2326.23 uGy*m? 00:14:45 hh:mm:ss 18.2 mGy/min
Slide 18: MAT - 10513, MRT - 10513
MAT - 10513, MRT - 10513 10513 Standard 190.3 mGy 2326.23 uGy*m? 00:14:45 hh:mm:ss 18.2 mGy/min
Slide 19: LIBERTY: Clinical and Regulatory Upcoming Milestones
LIBERTY: CLINICAL AND REGULATORY UPCOMING MILESTONES LIBERTY: LIBERTY: FDA LIBERTY: FDA 510(k) Pre-Submission Design Freeze Submission LIBERTY: 4Q21 3Q21 4Q22 One & Done System on-going LIBERTY: LIBERTY: Clinical Trial Initiate Animal 1Q22 Study 2021 2022 2023 20
Slide 20: Self-Cleaning Shunt (SCS)
SELF-CLEANING SHUNT (SCS): 21
Slide 21: SCS: Ventriculoperitoneal Shunt Market Opportunity
SELF-CLEANING SHUNT (SCS): VENTRICULOPERITONEAL SHUNT MARKET OPPORTUNITY Hydrocephalus and Normal Pressure Hydrocephalus (NPH), are medical conditions in which there is an abnormal accumulation of cerebrospinal fluid (CSF) in the ventricles of the brain. Over 1,000,000 people in the United States cu
Slide 22: Successful FDA Pre-Submission Meeting for Novel SCS Technology
SUCCESSFUL FDA PRE-SUBMISSION MEETING FOR NOVEL SCS TECHNOLOGY Affirmed Steps to Advance through the Next Developmental, Clinical & Regulatory Phases First-in-Human Clinical Trial under Apply for Limited EFS Expected to Clinical Investigation Start 3Q22 Early Feasibility Study (EFS) Design Freeze an
Slide 23: Robust IP Platform
ROBUST IP PLATFORM 24 41 patent patents applications issued/allowed pending worldwide Tip- Semi- Self- Multi-view Disposable Restenosis Robotic Double Propelled disposable Cleaning Imaging Endoluminal Prevention Crawler Concentric Endoscope Endoscope Shut System Robotic Guidewire System 24
Slide 24: Proven Founders
PROVEN FOUNDERS Prof. Moshe Shoham Harel Gadot Yossi Bornstein Member of the Scientific Advisory Board CEO, President & Chairman Co-Founder & Director Prof. Moshe Shoham is a worldwide acclaimed Mr. Harel Gadot was formerly a Worldwide Group Mr. Yossi Bornstein is the President of Shizim authority i
Slide 25: Proven Leadership Team
PROVEN LEADERSHIP TEAM Simon Sharon Dr. Eyal Morag David Ben Naim Chief Technology Officer Chief Medical Officer Chief Financial Officer Mr. Simon Sharon brings 23 years of R&D and Dr. Eyal Morag will lead the development and Mr. David Ben Naim is a CPA licensed in the general management in the medi
Slide 26: Summary
SUMMARY Addressing multi-billion, high growth, underserved markets Developing micro-invasive medical robotic technology platforms to enhance clinician ability to treat patients with unmet medical needs Multi-generational product pipeline portfolio with robust launch cadence Significant Intellectual
Microbot Medical — Investor Presentation (March 2021) on 6ix